Publications en collaboration avec des chercheurs de Universidad de Navarra (32)

2010

  1. Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells

    Biochemical Pharmacology, Vol. 79, Núm. 2, pp. 239-250

2009

  1. Neuroprotección en la enfermedad de parkinson: Análisis a través de la metodología de informadores clave

    Neurologia, Vol. 24, Núm. 2, pp. 113-124

2008

  1. Is good old minocycline a new neuroprotective drug?

    Revista de Neurologia, Vol. 47, Núm. 1, pp. 31-38

2007

  1. Minocycline and cytoprotection: Shedding new light on a shadowy controversy

    Current Drug Delivery, Vol. 4, Núm. 3, pp. 225-231

2005

  1. Malonate induces cell death via mitochondrial potential collapse and delayed swelling through an ROS-dependent pathway

    British Journal of Pharmacology, Vol. 144, Núm. 4, pp. 528-537

  2. Minocycline fails to protect cerebellar granular cell cultures against malonate-induced cell death

    Neurobiology of Disease, Vol. 20, Núm. 2, pp. 384-391

1997

  1. Entorhinal cortex of the rat: Cytoarchitectonic subdivisions and the origin and distribution of cortical efferents

    Hippocampus, Vol. 7, Núm. 2, pp. 146-183

1996

  1. Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum

    Neurology, Vol. 47, Núm. 1, pp. 219-224

  2. Consequences of nigrostriatal denervation on the γ-aminobutyric acidic neurons of substantia nigra pars reticulata and superior colliculus in parkinsonian syndromes

    Neurology, Vol. 46, Núm. 3, pp. 802-809

  3. Glutamic acid decarboxylase mRNA expression in medial and lateral pallidal neurons in the MPTP-treated monkey and patients with Parkinson's disease

    PARKINSON'S DISEASE

  4. Glutamic acid decarboxylase mRNA expression in medial and lateral pallidal neurons in the MPTP-treated monkey and patients with Parkinson's disease.

    Advances in neurology, Vol. 69, pp. 209-216

  5. Is dopaminergic cell death accompanied by concomitant nerve plasticity?

    PARKINSON'S DISEASE

  6. Metabolic activity of the basal ganglia in parkinsonian syndromes in human and non-human primates: A cytochrome oxidase histochemistry study

    Neuroscience, Vol. 71, Núm. 4, pp. 903-912

  7. Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis

    Brain, Vol. 119, Núm. 5, pp. 1717-1727

1995

  1. Chronic alcoholism decreases neuronal nuclear size in the human entorhinal cortex

    Neuroscience Letters, Vol. 183, Núm. 1-2, pp. 71-74

  2. Effects of Nigrostriatal Denervation and L‐Dopa Therapy on the GABAergic Neurons of the Striatum in MPTP‐treated Monkeys and Parkinson's Disease: An In Situ Hybridization Study of GAD67 mRNA

    European Journal of Neuroscience, Vol. 7, Núm. 6, pp. 1199-1209

  3. Neurotoxicity induced by prenatal exposure to MPTP on the monoaminergic and peptidergic systems of the marmoset brain

    Experimental Neurology, Vol. 131, Núm. 1, pp. 108-113

1994

  1. Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP–intoxicated monkeys: Effect of levodopa and GM1 ganglioside therapy

    Annals of Neurology, Vol. 36, Núm. 2, pp. 206-214

  2. Letters to the editor

    Movement Disorders

  3. MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration

    Neuroscience Letters, Vol. 175, Núm. 1-2, pp. 121-125